Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 219

1.

The microRNA miR-192/215 family is upregulated in mucinous ovarian carcinomas.

Agostini A, Brunetti M, Davidson B, Tropé CG, Eriksson AGZ, Heim S, Panagopoulos I, Micci F.

Sci Rep. 2018 Jul 23;8(1):11069. doi: 10.1038/s41598-018-29332-7.

2.

Activity and clinical relevance of autotaxin and lysophosphatidic acid pathways in high-grade serous carcinoma.

Onallah H, Catane LJ, Tropé CG, Hetland Falkenthal TE, Reich R, Davidson B.

Virchows Arch. 2018 Jul 21. doi: 10.1007/s00428-018-2418-x. [Epub ahead of print]

PMID:
30032361
3.

Evaluation of CHK1 activation in vulvar squamous cell carcinoma and its potential as a therapeutic target in vitro.

Wang Z, Førsund MS, Trope CG, Nesland JM, Holm R, Slipicevic A.

Cancer Med. 2018 Aug;7(8):3955-3964. doi: 10.1002/cam4.1638. Epub 2018 Jul 2.

4.

Expression of 14-3-3 sigma and eta proteins is unrelated to survival in metastatic high-grade serous carcinoma.

Davidson B, Holth A, Wang Z, Hellsylt E, Tropé CG, Hetland Falkenthal TE, Holm R.

APMIS. 2018 Apr;126(4):309-313. doi: 10.1111/apm.12816. Epub 2018 Feb 21.

PMID:
29464778
5.

Expression and clinical role of long non-coding RNA in high-grade serous carcinoma.

Filippov-Levy N, Cohen-Schussheim H, Tropé CG, Hetland Falkenthal TE, Smith Y, Davidson B, Reich R.

Gynecol Oncol. 2018 Mar;148(3):559-566. doi: 10.1016/j.ygyno.2018.01.004. Epub 2018 Jan 5.

PMID:
29310950
6.

Involvement of DPP9 in gene fusions in serous ovarian carcinoma.

Smebye ML, Agostini A, Johannessen B, Thorsen J, Davidson B, Tropé CG, Heim S, Skotheim RI, Micci F.

BMC Cancer. 2017 Sep 11;17(1):642. doi: 10.1186/s12885-017-3625-6.

7.

Epithelial-mesenchymal transition markers in malignant ovarian germ cell tumors.

Solheim O, Førsund M, Tropé CG, Kraggerud SM, Nesland JM, Davidson B.

APMIS. 2017 Sep;125(9):781-786. doi: 10.1111/apm.12715. Epub 2017 Jun 6.

PMID:
28585395
8.

TGFβ splicing and canonical pathway activation in high-grade serous carcinoma.

Gutgold N, Davidson B, Catane LJ, Holth A, Hellesylt E, Tropé CG, Dørum A, Reich R.

Virchows Arch. 2017 Jun;470(6):665-678. doi: 10.1007/s00428-017-2127-x. Epub 2017 Apr 21.

PMID:
28432432
9.

Genomic imbalances are involved in miR-30c and let-7a deregulation in ovarian tumors: implications for HMGA2 expression.

Agostini A, Brunetti M, Davidson B, Tropé CG, Heim S, Panagopoulos I, Micci F.

Oncotarget. 2017 Mar 28;8(13):21554-21560. doi: 10.18632/oncotarget.15795.

10.

Vulvar carcinoma in Norway: A 50-year perspective on trends in incidence, treatment and survival.

Meltzer-Gunnes CJ, Småstuen MC, Kristensen GB, Tropé CG, Lie AK, Vistad I.

Gynecol Oncol. 2017 Jun;145(3):543-548. doi: 10.1016/j.ygyno.2017.03.008. Epub 2017 Mar 27.

PMID:
28356187
11.

Recurrent fusion transcripts in squamous cell carcinomas of the vulva.

Brunetti M, Agostini A, Davidson B, Tropé CG, Heim S, Panagopoulos I, Micci F.

Oncotarget. 2017 Mar 7;8(10):16843-16850. doi: 10.18632/oncotarget.15167.

12.

Bilateral ovarian carcinomas differ in the expression of metastasis-related genes.

Smebye ML, Haugom L, Davidson B, Trope CG, Heim S, Skotheim RI, Micci F.

Oncol Lett. 2017 Jan;13(1):184-190. doi: 10.3892/ol.2016.5384. Epub 2016 Nov 14.

13.

Phospholipase D messenger RNA expression and clinical role in high-grade serous carcinoma.

Harel-Dassa K, Yedgar S, Tropé CG, Davidson B, Reich R.

Hum Pathol. 2017 Apr;62:115-121. doi: 10.1016/j.humpath.2016.12.023. Epub 2017 Jan 11.

PMID:
28087476
14.

Expressions of miR-30c and let-7a are inversely correlated with HMGA2 expression in squamous cell carcinoma of the vulva.

Agostini A, Brunetti M, Davidson B, Trope CG, Heim S, Panagopoulos I, Micci F.

Oncotarget. 2016 Dec 20;7(51):85058-85062. doi: 10.18632/oncotarget.13187.

15.

TSAP6 is a novel candidate marker of poor survival in metastatic high-grade serous carcinoma.

Broner EC, Tropé CG, Reich R, Davidson B.

Hum Pathol. 2017 Feb;60:180-187. doi: 10.1016/j.humpath.2016.10.017. Epub 2016 Nov 4.

PMID:
27825812
16.

Prognostic and clinicopathological significance of Cacna2d1 expression in epithelial ovarian cancers: a retrospective study.

Yu D, Holm R, Goscinski MA, Trope CG, Nesland JM, Suo Z.

Am J Cancer Res. 2016 Sep 1;6(9):2088-2097. eCollection 2016.

17.

Decreased expression of pyruvate dehydrogenase A1 predicts an unfavorable prognosis in ovarian carcinoma.

Li Y, Huang R, Li X, Li X, Yu D, Zhang M, Wen J, Goscinski MA, Trope CG, Nesland JM, Suo Z.

Am J Cancer Res. 2016 Sep 1;6(9):2076-2087. eCollection 2016.

18.

Ezrin Is Associated with Disease Progression in Ovarian Carcinoma.

Horwitz V, Davidson B, Stern D, Tropé CG, Tavor Re'em T, Reich R.

PLoS One. 2016 Sep 13;11(9):e0162502. doi: 10.1371/journal.pone.0162502. eCollection 2016.

19.

A novel truncated form of HMGA2 in tumors of the ovaries.

Agostini A, Panagopoulos I, Davidson B, Trope CG, Heim S, Micci F.

Oncol Lett. 2016 Aug;12(2):1559-1563. Epub 2016 Jun 29.

20.

MiR-29a is a candidate biomarker of better survival in metastatic high-grade serous carcinoma.

Nymoen DA, Slipicevic A, Holth A, Emilsen E, Hetland Falkenthal TE, Tropé CG, Reich R, Flørenes VA, Davidson B.

Hum Pathol. 2016 Aug;54:74-81. doi: 10.1016/j.humpath.2016.03.010. Epub 2016 Apr 8.

PMID:
27063471
21.
22.

Expression of zinc finger E-box-binding homeobox factor 1 in epithelial ovarian cancer: A clinicopathological analysis of 238 patients.

Li X, Huang R, Li RH, Trope CG, Nesland JM, Suo Z.

Mol Clin Oncol. 2016 Jan;4(1):18-22. Epub 2015 Oct 23.

23.

HUR mRNA expression in ovarian high-grade serous carcinoma effusions is associated with poor survival.

Davidson B, Holth A, Hellesylt E, Hadar R, Katz B, Tropé CG, Reich R.

Hum Pathol. 2016 Feb;48:95-101. doi: 10.1016/j.humpath.2015.09.027. Epub 2015 Oct 22.

PMID:
26640230
24.

Intra-Gene DNA Methylation Variability Is a Clinically Independent Prognostic Marker in Women's Cancers.

Bartlett TE, Jones A, Goode EL, Fridley BL, Cunningham JM, Berns EM, Wik E, Salvesen HB, Davidson B, Trope CG, Lambrechts S, Vergote I, Widschwendter M.

PLoS One. 2015 Dec 2;10(12):e0143178. doi: 10.1371/journal.pone.0143178. eCollection 2015.

25.

HOTAIR and its surrogate DNA methylation signature indicate carboplatin resistance in ovarian cancer.

Teschendorff AE, Lee SH, Jones A, Fiegl H, Kalwa M, Wagner W, Chindera K, Evans I, Dubeau L, Orjalo A, Horlings HM, Niederreiter L, Kaser A, Yang W, Goode EL, Fridley BL, Jenner RG, Berns EM, Wik E, Salvesen HB, Wisman GB, van der Zee AG, Davidson B, Trope CG, Lambrechts S, Vergote I, Calvert H, Jacobs IJ, Widschwendter M.

Genome Med. 2015 Oct 24;7:108. doi: 10.1186/s13073-015-0233-4.

26.

Expression and clinical role of chemoresponse-associated genes in ovarian serous carcinoma.

Nymoen DA, Hetland Falkenthal TE, Holth A, Ow GS, Ivshina AV, Tropé CG, Kuznetsov VA, Staff AC, Davidson B.

Gynecol Oncol. 2015 Oct;139(1):30-9. doi: 10.1016/j.ygyno.2015.07.107. Epub 2015 Jul 29.

PMID:
26232338
27.

MicroRNAs in Ovarian Cancer.

Katz B, Tropé CG, Reich R, Davidson B.

Hum Pathol. 2015 Sep;46(9):1245-56. doi: 10.1016/j.humpath.2015.06.013. Epub 2015 Jun 30. Review.

PMID:
26216350
28.

The expression of aldehyde dehydrogenase 1 (ALDH1) in ovarian carcinomas and its clinicopathological associations: a retrospective study.

Huang R, Li X, Holm R, Trope CG, Nesland JM, Suo Z.

BMC Cancer. 2015 Jul 7;15:502. doi: 10.1186/s12885-015-1513-5.

29.

Mitochondrial DNA Deficiency in Ovarian Cancer Cells and Cancer Stem Cell-like Properties.

Huang R, Wang J, Zhong Y, Liu Y, Stokke T, Trope CG, Nesland JM, Suo Z.

Anticancer Res. 2015 Jul;35(7):3743-53.

PMID:
26124317
30.

CIAPIN1 and ABCA13 are markers of poor survival in metastatic ovarian serous carcinoma.

Nymoen DA, Holth A, Hetland Falkenthal TE, Tropé CG, Davidson B.

Mol Cancer. 2015 Feb 18;14:44. doi: 10.1186/s12943-015-0317-1.

31.

Expression of CDK1(Tyr15), pCDK1(Thr161), Cyclin B1 (total) and pCyclin B1(Ser126) in vulvar squamous cell carcinoma and their relations with clinicopatological features and prognosis.

Wang Z, Slipicevic A, Førsund M, Trope CG, Nesland JM, Holm R.

PLoS One. 2015 Apr 7;10(4):e0121398. doi: 10.1371/journal.pone.0121398. eCollection 2015.

32.

HMGA2 expression pattern and TERT mutations in tumors of the vulva.

Agostini A, Panagopoulos I, Andersen HK, Johannesen LE, Davidson B, Tropé CG, Heim S, Micci F.

Oncol Rep. 2015 Jun;33(6):2675-80. doi: 10.3892/or.2015.3882. Epub 2015 Mar 30.

33.

Fertility and gonadal function after adjuvant therapy in women diagnosed with a malignant ovarian germ cell tumor (MOGCT) during the "cisplatin era".

Solheim O, Tropé CG, Rokkones E, Kærn J, Paulsen T, Salvesen HB, Hagen B, Vereide AB, Fosså SD.

Gynecol Oncol. 2015 Feb;136(2):224-9. doi: 10.1016/j.ygyno.2014.12.010. Epub 2014 Dec 12.

PMID:
25511159
34.

CD117 expression in fibroblasts-like stromal cells indicates unfavorable clinical outcomes in ovarian carcinoma patients.

Huang R, Wu D, Yuan Y, Li X, Holm R, Trope CG, Nesland JM, Suo Z.

PLoS One. 2014 Nov 7;9(11):e112209. doi: 10.1371/journal.pone.0112209. eCollection 2014.

35.

Ovarian cancer: diagnostic, biological and prognostic aspects.

Davidson B, Tropé CG.

Womens Health (Lond). 2014 Sep;10(5):519-33. doi: 10.2217/whe.14.37. Review.

PMID:
25335543
36.

Wee1 is a novel independent prognostic marker of poor survival in post-chemotherapy ovarian carcinoma effusions.

Slipicevic A, Holth A, Hellesylt E, Tropé CG, Davidson B, Flørenes VA.

Gynecol Oncol. 2014 Oct;135(1):118-24. doi: 10.1016/j.ygyno.2014.07.102. Epub 2014 Aug 2.

PMID:
25093290
37.

APOA1 mRNA expression in ovarian serous carcinoma effusions is a marker of longer survival.

Tuft Stavnes H, Nymoen DA, Hetland Falkenthal TE, Kærn J, Tropé CG, Davidson B.

Am J Clin Pathol. 2014 Jul;142(1):51-7. doi: 10.1309/AJCPD8NBSHXRXQL7.

PMID:
24926085
38.

Genomic profile of ovarian carcinomas.

Micci F, Haugom L, Abeler VM, Davidson B, Tropé CG, Heim S.

BMC Cancer. 2014 May 5;14:315. doi: 10.1186/1471-2407-14-315.

39.

The role of the tumor stroma in ovarian cancer.

Davidson B, Trope CG, Reich R.

Front Oncol. 2014 May 13;4:104. doi: 10.3389/fonc.2014.00104. eCollection 2014. Review.

40.

Prognostic factors in malignant ovarian germ cell tumours (The Surveillance, Epidemiology and End Results experience 1978-2010).

Solheim O, Gershenson DM, Tropé CG, Rokkones E, Sun CC, Weedon-Fekjaer H, Fosså SD.

Eur J Cancer. 2014 Jul;50(11):1942-50. doi: 10.1016/j.ejca.2014.03.288. Epub 2014 May 20.

PMID:
24857045
41.

VICKZ2 protein expression in ovarian serous carcinoma effusions is associated with poor survival.

Davidson B, Rosenfeld YB, Holth A, Hellesylt E, Tropé CG, Reich R, Yisraeli JK.

Hum Pathol. 2014 Jul;45(7):1520-8. doi: 10.1016/j.humpath.2014.03.005. Epub 2014 Mar 27.

PMID:
24814803
42.

BUB1 mRNA is significantly co-expressed with AURKA and AURKB mRNA in advanced-stage ovarian serous carcinoma.

Davidson B, Nymoen DA, Elgaaen BV, Staff AC, Tropé CG, Kærn J, Reich R, Falkenthal TE.

Virchows Arch. 2014 Jun;464(6):701-7. doi: 10.1007/s00428-014-1577-7. Epub 2014 Apr 23.

PMID:
24756216
43.

The clinical and diagnostic role of microRNAs in ovarian carcinoma.

Davidson B, Tropé CG, Reich R.

Gynecol Oncol. 2014 Jun;133(3):640-6. doi: 10.1016/j.ygyno.2014.03.575. Epub 2014 Apr 5. Review.

PMID:
24713546
44.

Chromosome 19 rearrangements in ovarian carcinomas: zinc finger genes are particularly targeted.

Smebye ML, Sveen A, Haugom L, Davidson B, Tropé CG, Lothe RA, Heim S, Skotheim RI, Micci F.

Genes Chromosomes Cancer. 2014 Jul;53(7):558-67. doi: 10.1002/gcc.22166. Epub 2014 Mar 14.

PMID:
24634323
45.

Low frequency of ESRRA-C11orf20 fusion gene in ovarian carcinomas.

Micci F, Panagopoulos I, Thorsen J, Davidson B, Tropé CG, Heim S.

PLoS Biol. 2014 Feb 4;12(2):e1001784. doi: 10.1371/journal.pbio.1001784. eCollection 2014 Feb.

46.

Sex hormone-binding globulin (SHBG) expression in ovarian carcinomas and its clinicopathological associations.

Huang R, Ma Y, Holm R, Trope CG, Nesland JM, Suo Z.

PLoS One. 2013 Dec 26;8(12):e83238. doi: 10.1371/journal.pone.0083238. eCollection 2013.

47.
48.

Long-term outcomes after pelvic radiation for early-stage endometrial cancer.

Onsrud M, Cvancarova M, Hellebust TP, Tropé CG, Kristensen GB, Lindemann K.

J Clin Oncol. 2013 Nov 1;31(31):3951-6. doi: 10.1200/JCO.2013.48.8023. Epub 2013 Sep 9.

PMID:
24019546
49.

Defining a prognostic marker panel for patients with ovarian serous carcinoma effusion.

Davidson B, Smith Y, Nesland JM, Kærn J, Reich R, Tropè CG.

Hum Pathol. 2013 Nov;44(11):2449-60. doi: 10.1016/j.humpath.2013.06.003. Epub 2013 Sep 5.

PMID:
24011953
50.

Malignant ovarian germ cell tumors: presentation, survival and second cancer in a population based Norwegian cohort (1953-2009).

Solheim O, Kærn J, Tropé CG, Rokkones E, Dahl AA, Nesland JM, Fosså SD.

Gynecol Oncol. 2013 Nov;131(2):330-5. doi: 10.1016/j.ygyno.2013.08.028. Epub 2013 Aug 31.

PMID:
24001518

Supplemental Content

Loading ...
Support Center